BRIGATINIB | BRIGATINIB | ATC L01ED04
ANTINEOPLASTIC TREATMENT OF ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) ALK TYROSINE KINASE INHIBITOR | ORAL | Cmax 2.4 MICROMOLAR Tmax 2.5 HOUR VD 153 LITER PPB 66 PERCENT Cl 12.7 LITER / HOUR HT 25 HOUR | ALK KINASE ROS1 IGF-1R FLT-3 EGFR PDB 5J7H (CRYSTAL STRUCTURE OF ANAPLASTIC LYMPHOMA KINASE (ALK) BOUND BY BRIGATINIB) LIGAND CODE = 6GY (link to the list of PDB complexes) Download experimental 3D coordinates of 6GY with added hydrogens | ALK tyrosine kinase receptor UNIPROT Q9UM73 ALK more at DrugCentral | EMA ANSM (in French) Inxight Drugs Dailymed Drugs.com SIDER side effects Chemical Probes Portal ChEMBL BindingDB DrugBank |